Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

779 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Phase II study of the PI3K inhibitor BKM120 in patients with advanced or recurrent endometrial carcinoma: a stratified type I-type II study from the GINECO group.
Heudel PE, Fabbro M, Roemer-Becuwe C, Kaminsky MC, Arnaud A, Joly F, Roche-Forestier S, Meunier J, Foa C, You B, Priou F, Tazi Y, Floquet A, Selle F, Berton-Rigaud D, Lesoin A, Kalbacher E, Lortholary A, Favier L, Treilleux I, Ray-Coquard I. Heudel PE, et al. Among authors: fabbro m. Br J Cancer. 2017 Jan;116(3):303-309. doi: 10.1038/bjc.2016.430. Epub 2017 Jan 10. Br J Cancer. 2017. PMID: 28072765 Free PMC article. Clinical Trial.
First-line high-dose sequential chemotherapy with rG-CSF and repeated blood stem cell transplantation in untreated inflammatory breast cancer: toxicity and response (PEGASE 02 trial).
Viens P, Palangié T, Janvier M, Fabbro M, Roché H, Delozier T, Labat JP, Linassier C, Audhuy B, Feuilhade F, Costa B, Delva R, Cure H, Rousseau F, Guillot A, Mousseau M, Ferrero JM, Bardou VJ, Jacquemier J, Pouillart P. Viens P, et al. Among authors: fabbro m. Br J Cancer. 1999 Oct;81(3):449-56. doi: 10.1038/sj.bjc.6690714. Br J Cancer. 1999. PMID: 10507769 Free PMC article. Clinical Trial.
Phase I study of high-dose topotecan with haematopoietic stem cell support in the treatment of ovarian carcinomas: the ITOV 01 protocol.
Lotz JP, Pautier P, Selle F, Viens P, Fabbro M, Lokiec F, Viret F, Gligorov J, Gosse B, Provent S, Ribrag V, Micléa JM, Dosquet C, Goetschel A, Cailliot C, Lefèvre G, Genève J, Lhommé C; Groupe d' Intensification des traitements des Tumeurs Ovariennes (ITOV Group). Lotz JP, et al. Among authors: fabbro m. Bone Marrow Transplant. 2006 Apr;37(7):669-75. doi: 10.1038/sj.bmt.1705310. Bone Marrow Transplant. 2006. PMID: 16501591 Clinical Trial.
Dose-dense adjuvant chemotherapy in node-positive breast cancer: docetaxel followed by epirubicin/cyclophosphamide (T/EC), or the reverse sequence (EC/T), every 2 weeks, versus docetaxel, epirubicin and cyclophosphamide (TEC) every 3 weeks. AERO B03 randomized phase II study.
Piedbois P, Serin D, Priou F, Laplaige P, Greget S, Angellier E, Teissier E, Berdah JF, Fabbro M, Valenza B, Herait P, Jehl V, Buyse M. Piedbois P, et al. Among authors: fabbro m. Ann Oncol. 2007 Jan;18(1):52-57. doi: 10.1093/annonc/mdl355. Epub 2006 Oct 17. Ann Oncol. 2007. PMID: 17047001 Free article. Clinical Trial.
779 results